1996-2003 yılları arasında takip ettiğimiz hodgkin ve hodgkin dışı lenfoma hastalarımızın değerlendirilmesi
Küçük Resim Yok
Tarih
2005
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada, Ocak 1996 ile Aralık 2003 tarihleri arasında Selçuk Üniversitesi Meram Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı'nda, Hodgkin ve Hodgkin dışı lenfoma teşhisi konularak tedavi edilen 79 kadın, 88 erkek; 48'i HH, 119'u HDL olmak üzere toplam 167 hastanın klinik ve laboratuar parametreleri, tedavi sonuçlan, yaşam süreleri incelenmiş, elde edilen veriler literatür bilgileri ile karşılaştırılmıştır.Yaş ortalaması, HH'da 40, HDL'lı hastalarda 57; erkek kadın oranı, HH'nda 1.28/1 iken HDL'da 1.05/1 bulunmuştur. Kaynaklardaki bilgilerle uyumlu olarak her iki hastalıkta da en sık doktora başvuru sebebi semptomsuz lenfadenomegalilerdir. Görülme oranlan değişmekle beraber, hastalarda, şişlik, halsizlik, ateş, kilo kaybı, gece terlemesi, iştahsızlık, kaşıntı, nefes darlığı şikâyetleri vardı. Fizik muayene bulgulan incelendiğinde literatür bilgileri ile uyumlu olarak, her iki hastalık grubunda da en sık servikal bölge lenf nodlar tutulmuştur. HH'nm hepsinde hastalık lenfatik bölgelerden başlarken, HDL'lı hastalann %12'sinde ekstralenfatik bölgelerden (mide, meme, cilt, orbita, testis) başlamıştır. Teşhis, tutulum yerlerinden biopsi alınarak konulmuştur. HH'nda Rye sınıflamasına göre, %45,7 mikst sellüler, %28,6 nodüler sklerozan, %20 lenfositten zengin, %5,7 lenfositten fakir tip; Ann Arbor evreleme sistemine göre, %22,7 evre I, %15,9 evre İL %52,3 evre m, %9,1 evre IV'de hasta tesbit edilmiştir. HDL'da Working Formulation'a göre, %22 low grade, %45 intermediate grade, %33 high grade; Ann Arbor evreleme sistemine göre, %20,6 evre I, %21,6 evre IL %46 evre IH, %11,8 evre IV'de hasta bulunmuştur. Literatür bilgileri ile uyumlu olarak, HH'da, en çok ABVD, MOPP ve MOPP/ABVD; HDL'da, CHOP içeren kemoterapi protokolleri ve evrelerine göre radyoterapi uygulanmıştır. HH'da median yaşam süresi 16 yıl (192 ay), 5 yıl yaşama ihtimali %83, 10 yıl yaşama ihtimali literatür bilgileri ile uyumlu olarak %70 bulunmuştur. HDL'da median yaşam süresi 42 ay (3,5 yıl), 5 yıl yaşama ihtimali ise %35 olarak bulunmuştur. Tabiî ki daha kesin sonuçlara ulaşmak için vaka sayısının fazla olduğu çok merkezli çalışmalara ihtiyaç vardır.
Total of 167, 79 female and 88 male patients who were followed up with the diagnosis of Hodgkin's disease (HD)(48 patients) and non-Hodgkin lymphoma (NHL) (119 patients) between January 1996 and December 2003 in the Selçuk University Faculty of Medicine, Department of Hematology were enrolled in this study. These patients' clinical and laboratory parameters, treatment results and survival rates were analyzed and the data were compared with the literature. The mean ages were 40 years for HD and 57 years for NHL; and male/female ratio was 1.28/1 for HD and 1.05/1 for NHL. It is well adjusted with the literature that the main reason for admitting to doctor was enlarged but otherwise asymptomatic lumps. Although the incidence of symptoms were changeable; lumps, fatigue, fever, weight loss, night sweats, lack of appetite, itching and breathlessness were the major complaints. Similar with the literature, servical lymph nodes of the patients were mostly involved in both illness. All the HD cases were manifested with nodal sites involvement where as, in the 12% of NHL, the illness had begun from extranodal sites such as stomach, breast, skin, orbita and testes. Diagnosis was drawn as a result of biopsy from involved sites. According to the Rye Classification, mixed cellularity, nodular sclerosis, lymphocyte-rich and lymphocyte-depleted types HD were diagnosed in 45,7%, 28,6%, 20%, 5,7% of patients, respectively and according to the Ann Arbor Staging System, 22,7% stage I, 15,9% stage II, 52,3% stage III and 9,1% stage IV patients were determined. According to the Working Formulation, low grade, intermediate grade and high grade NHL were diagnosed in 22%, 45%, 33% of patients, respectively and according to the Ann Arbor Staging System, 20,6% stage I, 21,6% stage II, 46% stage III, 11,8% stage IV patients were determined. In consistent with the literature, ABVD, MOPP and MOPP/ABVD protocols were used in HD treatment where as CHOP containing protocols were used in NHL. On the other hand, radiotheraphy was performed according to the stages. The median survival time in HD was 16 years(192 months)and the overall survival rates at 5 and 10 years were 83% and 70%, respectively. The median survival time in NHL was 42 months(3,5 years)and the overall survival rate at 5 years were 35%. We concluded that, in order to obtain more clarifying results, multicentered comprehensive studies are obligatory.
Total of 167, 79 female and 88 male patients who were followed up with the diagnosis of Hodgkin's disease (HD)(48 patients) and non-Hodgkin lymphoma (NHL) (119 patients) between January 1996 and December 2003 in the Selçuk University Faculty of Medicine, Department of Hematology were enrolled in this study. These patients' clinical and laboratory parameters, treatment results and survival rates were analyzed and the data were compared with the literature. The mean ages were 40 years for HD and 57 years for NHL; and male/female ratio was 1.28/1 for HD and 1.05/1 for NHL. It is well adjusted with the literature that the main reason for admitting to doctor was enlarged but otherwise asymptomatic lumps. Although the incidence of symptoms were changeable; lumps, fatigue, fever, weight loss, night sweats, lack of appetite, itching and breathlessness were the major complaints. Similar with the literature, servical lymph nodes of the patients were mostly involved in both illness. All the HD cases were manifested with nodal sites involvement where as, in the 12% of NHL, the illness had begun from extranodal sites such as stomach, breast, skin, orbita and testes. Diagnosis was drawn as a result of biopsy from involved sites. According to the Rye Classification, mixed cellularity, nodular sclerosis, lymphocyte-rich and lymphocyte-depleted types HD were diagnosed in 45,7%, 28,6%, 20%, 5,7% of patients, respectively and according to the Ann Arbor Staging System, 22,7% stage I, 15,9% stage II, 52,3% stage III and 9,1% stage IV patients were determined. According to the Working Formulation, low grade, intermediate grade and high grade NHL were diagnosed in 22%, 45%, 33% of patients, respectively and according to the Ann Arbor Staging System, 20,6% stage I, 21,6% stage II, 46% stage III, 11,8% stage IV patients were determined. In consistent with the literature, ABVD, MOPP and MOPP/ABVD protocols were used in HD treatment where as CHOP containing protocols were used in NHL. On the other hand, radiotheraphy was performed according to the stages. The median survival time in HD was 16 years(192 months)and the overall survival rates at 5 and 10 years were 83% and 70%, respectively. The median survival time in NHL was 42 months(3,5 years)and the overall survival rate at 5 years were 35%. We concluded that, in order to obtain more clarifying results, multicentered comprehensive studies are obligatory.
Açıklama
Anahtar Kelimeler
hodgkin, lenfoma, lymphoma
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Hidayetoğlu, B. T. (2005). 1996-2003 yılları arasında takip ettiğimiz hodgkin ve hodgkin dışı lenfoma hastalarımızın değerlendirilmesi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Dahili Tıp Bilimleri İç Hastalıklar Anabilim Dalı, Konya.
